Devonyu Clearmind Medicine ( CMND ) said it has secured the exclusive global rights to develop, manufacture and commercialize psychedelic compounds invented by certain professors at Israel’s Hebrew University for the potential treatment of post-traumatic stress disorder and other mental health conditions. Under the agreement, Clearmind will be responsible for ongoing development and future commercialization. The deal also includes future milestone payments and royalties on sales.
More on CONMED CONMED Corporation 2024 Q1 - Results - Earnings Call Presentation CONMED Corporation (CNMD) Q1 2024 Earnings Call Transcript CONMED Non-GAAP EPS of $0.79 beats by $0.05, revenue of $312.
3M beats by $5.58M CONMED Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on CONMED.
